Torrent Pharmaceuticals Ltd - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Issue of Duplicate Share Certificate02-11-2019
02-11-2019
TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate25-10-2019
Torrent Pharma share price closes over 5% higher on Q2 earnings
Torrent Pharmaceuticals share price rose up to 6.92% intra day to Rs 1,797 compared to the previous close of Rs 1,680 on BSE. The stock closed 5.13% or 86.25 points lower at Rs 1,766.75 on BSE.24-10-2019
Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Investor Presentation
The presentation on unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2019 to be made to analysts is enclosed for your records23-10-2019
Torrent Pharmaceuticals Ltd - 500420 - Submission / Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements), 2015, ('Listing Regulations')
We would like to inform that the Board has at its meeting held today approved, inter-alia, the Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with the limited review report of the Company for the quarter and half year ended on 30th September, 2019. The said financial results are enclosed herewith. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of Unaudited Consolidated Financial Results for the quarter and half year ended on 30th September, 2019. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com. A Press Release on Financial Results which is being submitted to the media is also enclosed herewith.23-10-2019
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
In furtherance to our letter dated 16-Oct-19 on the captioned subject, we would like to inform that the teleconference with Investors / Analyst has been rescheduled to 06:00 P.M. from 06:30 P.M on 23rd October, 2019 to discuss the financial performance of the Company for the quarter and half year ended 30th September, 2019. The Dial-in details shall remain same as mentioned in our letter dated 16-Oct-19. The above is for your information and record.18-10-2019
TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate17-10-2019
Torrent Pharmaceuticals Ltd - 500420 - Shareholding for the Period Ended September 30, 2019
Torrent Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here17-10-2019
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We hereby inform that the Company has scheduled a teleconference with Investors / Analyst on 23rd October, 2019 at 06:30 P.M. to discuss the financial performance of the Company for the quarter and half year ended 30th September, 2019.16-10-2019
US FDA warning letter to Torrent Pharma blames management for violations
US FDA has issued a warning letter to Indrad plant of the company following an inspection of the facility in April.US FDA directed the company to immediately and comprehensively assess its global manufacturing operations16-10-2019